| Literature DB >> 34429580 |
Diana Dmuchowska1, Izabela Cwalina1, Pawel Krasnicki1, Joanna Konopinska1, Emil Saeed1, Zofia Mariak1, Iwona Obuchowska1.
Abstract
PURPOSE: This study assessed the effect of three waves of the COVID-19 pandemic primarily on the number and timing of referrals due to rhegmatogenous retinal detachment (RRD) and secondarily on the demographic or clinical characteristics of patients. PATIENTS AND METHODS: A retrospective single-centre analysis of medical records included 247 eyes from 247 patients who underwent primary RRD repair with (phaco) vitrectomy between January 1, 2019, and May 31, 2021.Entities:
Keywords: SARS-CoV-2; lockdown; ophthalmic epidemiology; public health
Year: 2021 PMID: 34429580 PMCID: PMC8378894 DOI: 10.2147/OPTH.S323998
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Characteristics of Patients with RRD Treated in the Pre-COVID Era and During the COVID-19 Pandemic
| Pre-COVID Year (March 2019 – February 2020) | First COVID Year (March 2020 – February 2021) | p | |
|---|---|---|---|
| N | 121 | 101 | 0.179 |
| Sex, n (%) | |||
| Female | 50 (41.3) | 50 (49.5) | 0.278 |
| Male | 71 (58.7) | 51 (50.5) | |
| Age, years, mean±SD | 63.15±12.67 | 60.53±12.77 | 0.120 |
| Duration of symptoms, days, median (Q1;Q3) | 8.50 (5.00;26.25) | 10.00 (7.00;29.50) | 0.746 |
| Operated eye, n (%) | |||
| Left | 61 (50.4) | 46 (45.5) | 0.557 |
| Right | 60 (49.6) | 55 (54.5) | |
| Pre-operative logMAR CDVA, median (Q1;Q3) | 2.40 (0.70;2.70) | 1.70 (1.00;2.70) | 0.541 |
| AXL, mean±SD | 24.67±2.02 | 24.62±1.88 | 0.876 |
| Lens status, n (%) | |||
| Phakic | 80 (66.1) | 70 (69.3) | 0.645 |
| Pseudophakic | 39 (32.2) | 28 (27.7) | |
| Aphakic | 2 (1.7) | 3 (3.0) | |
| Macula status, n (%) | |||
| On | 18 (14.9) | 17 (16.8) | 0.831 |
| Off | 103 (85.1) | 84 (83.2) | |
| Tamponade, n (%) | |||
| SF6 | 58 (47.9) | 40 (39.6) | 0.268 |
| Silicone oil | 63 (52.1) | 61 (60.4) |
Notes: Pre-COVID and COVID populations compared with t-test for age and AXL, Mann–Whitney U-test for duration of symptoms and logMAR of operated eye, chi-square goodness-of-fit test for number of patients, Pearson’s independence chi-square test for sex, operated eye, tamponade and with Fisher exact test for lens status and macula.
Abbreviations: N, number; Q1 Q3, quartile 1 quartile 3; interquartile range; logMAR, the logarithm of the minimum angle of resolution; CDVA, corrected distance visual acuity; AXL, axial length; SF6, sulphur hexafluoride.
Characteristics of Patients with RRD Treated During the Three Waves of the COVID-19 Pandemic and in Corresponding Months of 2019
| Wave 1 | Wave 2 | Wave 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-COVID (Mar 2019-May 2019) | COVID (Mar 2020-May 2020) | p | Pre-COVID (Oct 2019-Dec 2019) | COVID (Oct 2020-Dec 2020) | p | Pre-COVID (Mar 2019-Apr 2019) | COVID (Mar 2021-Apr 2021) | p | |
| N | 31 | 16 | 0.029 | 27 | 22 | 0.475 | 23 | 17 | 0.343 |
| Sex, n (%) | |||||||||
| Female | 15 (48.4) | 11 (68.8) | 0.307 | 12 (44.4) | 11 (52.4) | 0.772 | 10 (43.5) | 7 (41.2) | >0.999 |
| Male | 16 (51.6) | 5 (31.3) | 15 (55.6) | 10 (47.6) | 13 (56.5) | 10 (58.8) | |||
| Age, years, mean±SD | 65.07±12.11 | 61.50±9.78 | 0.279 | 61.67±13.32 | 63.51±9.37 | 0.626 | 65.55±13.30 | 63.31±12.99 | 0.591 |
| Duration of symptoms, days, median (Q1;Q3) | 8.50 (5.50;50.25) | 14.00 (7.00;60.00) | 0.499 | 7.00 (4.00;14.00) | 10.00 (7.00;19.25) | 0.105 | 7.00 (4.00;15.75) | 14.00 (4.00;30.00) | 0.646 |
| Operated eye, n (%) | |||||||||
| Left | 15 (48.4) | 7 (43.8) | >0.999 | 13 (48.1) | 10 (47.6) | >0.999 | 11 (47.8) | 12 (70.6) | 0.264 |
| Right | 16 (51.6) | 9 (56.3) | 14 (51.9) | 11 (52.4) | 12 (52.2) | 5 (29.4) | |||
| Pre-operative logMAR CDVA, median (Q1;Q3) | 2.70 (1.70;2.70) | 1.96 (0.93;2.70) | 0.179 | 1.70 (0.70;2.70) | 1.70 (1.22;2.70) | 0.534 | 2.70 (1.35;2.70) | 2.40 (0.30;2.70) | 0.569 |
| AXL, mean±SD | 24.95±2.25 | 24.48±1.87 | 0.516 | 25.25±2.22 | 23.92±1.74 | 0.064 | 24.99±2.03 | 24.54±1.15 | 0.484 |
| Lens status, n (%) | |||||||||
| Phakic | 21 (67.7) | 13 (81.3) | 0.669 | 15 (55.6) | 14 (66.7) | 0.116 | 16 (69.6) | 11 (64.7) | >0.999 |
| Pseudophakic | 9 (29.0) | 3 (18.8) | 12 (44.4) | 5 (23.8) | 7 (30.4) | 6 (35.3) | |||
| Aphakic | 1 (3.2) | 0 (0.0) | 0 (0.0) | 2 (9.5) | 0 (0.0) | 0 (0.0) | |||
| Macula status, n (%) | |||||||||
| On | 4 (12.9) | 3 (18.8) | 0.676 | 5 (18.5) | 2 (9.5) | 0.445 | 3 (13.0) | 5 (29.4) | 0.250 |
| Off | 27 (87.1) | 13 (81.3) | 22 (81.5) | 19 (90.5) | 20 (87.0) | 12 (70.6) | |||
| Tamponade, n (%) | |||||||||
| SF6 | 12 (38.7) | 7 (43.8) | 0.673 | 13 (48.1) | 5 (23.8) | 0.154 | 10 (43.5) | 7 (41.2) | >0.999 |
| Silicone oil | 19 (61.3) | 9 (56.3) | 14 (51.9) | 16 (76.2) | 13 (56.5) | 10 (58.8) | |||
Notes: Pre-COVID and COVID populations compared with t-test for age and AXL, Mann–Whitney U-test for duration of symptoms and logMAR of operated eye, chi-square goodness-of fit test for number of patients, Pearson’s independence chi-square test for sex, operated eye, tamponade and with Fisher exact test for lens status and macula.
Abbreviations: N, number; Q1 Q3, quartile 1 quartile 3; logMAR, the logarithm of the minimum angle of resolution; CDVA, corrected distance visual acuity; AXL, axial length; SF6, sulphur hexafluoride.
Figure 1Monthly number of patients undergoing primary rhegmatogenous retinal detachment surgeries between January 2019 and May 2021 (total n= 247). Blue line represents % change in number for a given month vs corresponding month in 2019 with reference on the right axis (eg −18.2% for Oct 2020 means that number of operated patients was 18.2% lower than in Oct 2019) (raw data in ).
Characteristics of Patients with Primary Rhegmatogenous Retinal Detachment Treated During the Three Waves of the COVID-19 Pandemic
| COVID Wave 1 (Mar 2020–May 2020) | COVID Wave 2 (Oct 2020–Dec 2020) | COVID Wave 3 (Mar 2021–Apr 2021) | p | |
|---|---|---|---|---|
| N | 16 | 22 | 17 | 0.569 |
| Sex, n (%) | ||||
| Female | 11 (68.8) | 11 (52.4) | 7 (41.2) | 0.280 |
| Male | 5 (31.3) | 10 (47.6) | 10 (58.8) | |
| Age, years, mean±SD | 61.50±9.78 | 63.51±9.37 | 63.31±12.99 | 0.688 |
| Duration of symptoms, days, median (Q1;Q3) | 14.00 (7.00;60.00) | 10.00 (7.00;19.25) | 14.00 (4.00;30.00) | 0.770 |
| Operated eye, n (%) | ||||
| Left | 7 (43.8) | 10 (47.6) | 12 (70.6) | 0.235 |
| Right | 9 (56.3) | 11 (52.4) | 5 (29.4) | |
| Pre-operative logMAR CDVA, median (Q1;Q3) | 1.96 (0.93;2.70) | 1.70 (1.22;2.70) | 2.40 (0.30;2.70) | 0.896 |
| AXL, mean±SD | 24.48±1.87 | 23.92±1.74 | 24.54±1.15 | 0.216 |
| Lens status, n (%) | ||||
| Phakic | 13 (81.3) | 14 (66.7) | 11 (64.7) | 0.536 |
| Pseudophakic | 13 (18.3) | 5 (23.8) | 6 (35.3) | |
| Aphakic | 0 (0.0) | 2 (9.5) | 0 (0.0) | |
| Macula status, n (%) | ||||
| On | 3 (18.8) | 2 (9.5) | 5 (29.4) | 0.313 |
| Off | 13 (81.3) | 19 (90.5) | 12 (70.6) | |
| Tamponade, n (%) | ||||
| SF6 | 7 (43.8) | 5 (23.8) | 7 (41.2) | 0.373 |
| Silicone oil | 9 (56.3) | 16 (76.2) | 10 (58.8) |
Notes: COVID populations during three waves compared with ANOVA for age and AXL, Kruskal–Wallis test for duration of symptoms and logMAR of operated eye, chi-square goodness-of fit test for number of patients, Pearson’s independence chi-square test for sex, operated eye, tamponade and with Fisher exact test for lens status and macula.
Abbreviations: N, number; Q1 Q3, quartile 1 quartile 3; logMAR, the logarithm of the minimum angle of resolution; CDVA, corrected distance visual acuity; AXL, axial length; SF6, sulphur hexafluoride.